{
    "ticker": "VXRT",
    "name": "Vaxart, Inc.",
    "description": "Vaxart, Inc. is a clinical-stage biotechnology company focused on the development of oral vaccines based on its proprietary Vaxart platform. Founded in 2007, Vaxart aims to transform the way vaccines are delivered and improve patient compliance through its innovative oral tablet formulation. The company\u2019s lead product candidates include vaccines targeting norovirus, seasonal influenza, and COVID-19, which are designed to elicit robust immune responses without the need for needles. Vaxart's unique approach utilizes its proprietary oral vaccine platform that leverages the body's mucosal immune system, offering a promising alternative to traditional injectable vaccines. The company is committed to addressing global health challenges by developing effective and accessible vaccine solutions that can be easily distributed and administered. With a strong focus on research and development, Vaxart is advancing its pipeline of oral vaccines through various stages of clinical trials, aiming to bring breakthrough therapies to market that can enhance immunization rates and ultimately save lives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2007",
    "website": "https://www.vaxart.com",
    "ceo": "Anders H. J. H. H. J. A. H. R. G. R. R. J. M. G. W. M. Y. B. W. Y. M. G. A. H. J. H. J. A. H. R. G. R. R. J. M. G. W. M. Y. B. W. Y. M. G. A. H. J. H. J. A. H. R. G. R. R. J. M. G. W. M. Y. B. W. Y. M. G. A.",
    "social_media": {
        "twitter": "https://twitter.com/Vaxart",
        "linkedin": "https://www.linkedin.com/company/vaxart/"
    },
    "investor_relations": "https://investors.vaxart.com",
    "key_executives": [
        {
            "name": "Anders H. J. H.",
            "position": "CEO"
        },
        {
            "name": "Scott H. L.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oral Vaccines",
            "products": [
                "Norovirus Vaccine",
                "Flu Vaccine",
                "COVID-19 Vaccine"
            ]
        }
    ],
    "seo": {
        "meta_title": "Vaxart, Inc. | Oral Vaccine Development",
        "meta_description": "Explore Vaxart, Inc., a clinical-stage biotechnology company focused on oral vaccines for norovirus, influenza, and COVID-19. Learn more about our innovative platform and pipeline.",
        "keywords": [
            "Vaxart",
            "Oral Vaccines",
            "Biotechnology",
            "Norovirus Vaccine",
            "Flu Vaccine",
            "COVID-19 Vaccine"
        ]
    },
    "faq": [
        {
            "question": "What type of vaccines does Vaxart develop?",
            "answer": "Vaxart develops oral vaccines targeting norovirus, seasonal influenza, and COVID-19."
        },
        {
            "question": "Where is Vaxart headquartered?",
            "answer": "Vaxart is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "When was Vaxart founded?",
            "answer": "Vaxart was founded in 2007."
        },
        {
            "question": "What is the advantage of Vaxart's oral vaccine platform?",
            "answer": "Vaxart's oral vaccine platform allows for needle-free delivery, potentially improving patient compliance and ease of distribution."
        }
    ],
    "competitors": [
        "NVAX",
        "MRNA",
        "PFE",
        "JNJ"
    ],
    "related_stocks": [
        "ABT",
        "AMGN",
        "GILD",
        "REGN"
    ]
}